Optum Compounding Services, LLC, Phoenix, AZ
Is Optum Compounding Services, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “De-registered as an Outsourcing Facility - Ceased Compounding Operations”.
Does Optum Compounding Services, LLC hold a Arizona pharmacy license?
State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.
Has Optum Compounding Services, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Apr 11, 2022) for Optum Compounding Services, LLC. State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Optum Compounding Services, LLC
- Location
- Phoenix, AZ
- Type as FDA labels it
- 503A
- FDA’s note
- De-registered as an Outsourcing Facility - Ceased Compounding Operations
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Apr 11, 2022
- FDA Data Dashboard inspections
- 3 inspections: 2 VAI, 1 NAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 3 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Optum Compounding Services, LLC, a 503A facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Apr 11, 2022 | FMD-145 letter | FMD-145 Letter Issued 04/11/2022 | Not linked by FDA |
| Aug 13, 2021 | Form 483 | 483 Issued 08/13/2021 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Optum Compounding Services, LLC, Phoenix, AZ (FEI number 3012890460), matched to this page by exact name, city and state. It lists 3 inspections: 2 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Aug 13, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3012890460 | 1148980 |
| Apr 20, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3012890460 | 1048973 |
| Apr 24, 2017 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3012890460 | 1013242 |
Form 483s FDA has published for this site
- Aug 13, 2021: Form 483 to Optum Compounding Services, LLC, published Dec 22, 2021. fda.gov
- Apr 20, 2018: Form 483 to Optum Compounding Services, LLC, published Mar 23, 2026. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 2, 2021 to Aug 13, 2021: 3 observations
- Firm on the cover
- Optum C ompoundi ng Se rvi ces, LL C, 244 16 N 1 9t h Ave, P hoenix, A Z 8 5085-18 87
- FEI number
- 3012890460
- Establishment type on the cover
- Outs ourcing Faci lity
- FDA district office on the cover
- Not read
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.
Specifically,
A) The visual inspection program is inadequate to ensure defected/non-conforming syringes can be accurately rejected. For example: 1.Bevacizumab 2mg/0.08ml lot #138-20213103@12 was 100% visually inspected on 04/07/21 and 04/16/21 resulting in <Redacted B4> non-conforming units out of a total of <Redacted B4> resulting in a rejectable defect of <Redacted B4>% . The specification is <Redacted B4>%. The non-conforming units were identified as follows: Fibers/Lint Black Particles White Particles Clear Particles Barrel defects Plunger defects Leakage behind the plunger <Redacted B4> The acceptable units from this batch were re-inspected on 04/20/21 resulting in an additlonal <Redacted B4> non-conforming units out of a total of <Redacted B4> resulting in a rejectable defect of <Redacted B4>%. The specification for a re-inspection is <Redacted B4>%. ...
Observation 2
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically,
A) QRE 27255 was opened to Investigation an adverse event associated with Bevaclzumab lot #138 20191212@3. The investigation is inadequate in t hat the retain samples were not retested for parameters such as, but not limited to, sub visible particles.
B) Investigation into QRE #25723, dated 12/16/2019, was initiated due to a customer complaint regarding a fiber that was found in a syringe of Bevacizumab <Redacte d B4> 1.25mg/0.05ml lot #138-20192110@17. The Investigation was Inadequate In that It did not identify what the fiber was.
C) Although the majority of particles identified in filled syringes during visual inspection have been attributed to t he lubricant <Redacted B 4> a CA PA h as n ot be en implemented to adequate ly redu ce or eliminate the presence of particles in finished product.
Observation 3
Drug product containers or closures are additive so as to alter the safety, identity, strength, quality, and purity of the drug beyond the official or established requirements.
Specifically, the <Redacte d B4> lubricant used in <Reda cted B4> Normject syringes was identified as a cause of white particles seen In finished product bevaclzumab, which are rejected when observed. Additionally, the suppl ier of these syringes has not been re-audited or re-su rveyed when these quality related issues were identifi ed, as mentioned by procedure: OCS-SOP-011, Qualification of Vendors, Effective Date: 11/17/2020, Version 1.
Linked 483s whose text is not shown
- Apr 20, 2018: FDA document 112827: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.